Improved SpO 2 Accuracy Now Available for All Patient Populations IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that RD SET ® sensors with Masimo Measure-through Motion and ...
When a patient is receiving supplemental oxygen during surgery, there’s a risk that they’ll develop hyperoxia, where their arterial blood becomes oxygenated above normal levels, potentially leading to ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking and release of RD rainbow Lite SET™ sensors, which enable the monitoring of Masimo Oxygen Reserve Index™ ...
Irvine, California-based Masimo Technologies, which makes non-invasive patient monitoring devices and sensors, has received FDA 510(k) clearance for its forehead sensor. The adhesive TFA-1 Forehead ...
More than a decade into their partnership, Masimo and GE HealthCare are still finding new ways to combine their respective patient monitoring technologies. In the latest expansion of their ...
CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...
OBJECTIVE: Pulse oximetry is a standard of care for monitoring oxygenation in neonates. Associated with the use of pulse oximetry is the cost of patient sensors, especially if the sensor is designed ...
Pune, Maharashtra, October 14 2022 (Wiredrelease) Market.Biz –:What Is The Current Situation Of SpO2 Sensors Global Market After The Covid 19, The Russia-Ukraine War, and The Sri Lankan Economy Crisis ...
Masimo MASI announced that the FDA has granted De Novo status to its noninvasive, continuous parameter — ORi (Oxygen Reserve Index) — designed to provide additional insight into a patient’s oxygen ...
Masimo Corporation MASI recently received the CE mark for its SafetyNet Alert and introduced the same in western Europe. Masimo SafetyNet Alert is an arterial blood oxygen saturation monitoring and ...
Masimo Corp. ((MASI)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results